Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$10.90
▼ $1.44 (-11.7%)
Market data updated: 10/01 12:41 AM
Fundamentals updated: 10/01/2026
News analyzed: 10/01/2026
Market Cap
Not available
Day Range
$10.22 - $11.17
52-Week Range
$4.62 - $13.28
Beta
—
Next Earnings
03.11.2026
Support
$7.82
Resistance
$12.93
TRLV is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+47.7% (1Y)
Strengths: 18/32 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $18.03 vs. price $10.90 (+65.5%)
Fair Value
Biggest negative driver
Net margin
Net margin: -10.3% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 0 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 0
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
63
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
47
Value
62
Momentum
73
Risk
46
Sentiment
80
Fundamental
49
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Trulieve Cannabis Corp. has focused on its strategic growth and market recognition. The company announced an exclusive master licensing agreement with Connected for Florida and Texas, securing rights to Alien Labs and Connected-branded cannabis products. Additionally, Trulieve was added to the S&P Total Market and Completion Indices, along with healthcare sub-indices, highlighting its strong market performance and stability. Analysts also noted its outperformance in 2026, positioning it as a leader in the U.S. medical cannabis sector.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Trulieve Cannabis Corp. Subordinate Voting. News trend score: 80. Reason: 6 of the last 9 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
38
🎯 Conviction (vs. Emotion)
37
Psychology
50
Fundamentals
49
Technical
73
Valuation
62
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price (3M)
+30%
Market Narrative
55
Fundamental Reality
37
Narrative Gap
+18
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 15/100
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 89
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 63
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 60
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 56
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 53
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 53
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 51
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 46
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 43
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 39
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 38
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 33
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 32
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 15
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 250 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 3 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
60.2%
Operating Margin
12.1%
Net Margin
-10.3%
EBITDA Margin
22.1%
ROE
-10.7%
ROA
-4.5%
ROIC
—
EPS
-$0.58
Cash
$255.53M
Total Debt
$136.74M
Current Ratio
4.43
Debt/Equity
0.12
How is Fair Value calculated? →
Current Price
$10.90
Estimated Fair Value (DCF)
$18.03
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+65.5%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
-0.9%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | -0.9% | $226.58M | $207.88M |
| 2 | -0.0% | $226.48M | $190.62M |
| 3 | 0.8% | $228.30M | $176.29M |
| 4 | 1.7% | $232.07M | $164.40M |
| 5 | 2.5% | $237.87M | $154.60M |
Base FCF (last actual year)
$228.63M
Terminal Value
$3.75B
Present Value of Terminal Value
$2.44B
Enterprise Value
$3.33B
Net Debt
$-118.79M
Equity Value
$3.45B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$5.97
Tangible Book Value per Share (Tangible NAV)
-$0.73
Sentiment based on basic keywords (not AI) — 6 positive, 2 neutral, 1 negative out of the last 9 articles.
Benzinga · 30.9.2026
Benzinga · 30.9.2026
Yahoo · 30.9.2026
ChartMill · 29.9.2026
Benzinga · 29.9.2026
Yahoo · 28.9.2026
Yahoo · 22.9.2026
Yahoo · 22.9.2026
Benzinga · 22.9.2026
Trulieve Cannabis Corp. Subordinate Voting (TRLV) currently has a StockIQ AI score of 63/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
TRLV currently scores 63/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, TRLV's estimated fair value is $18.03, which is 65.5% above the current price of $10.90. This is one valuation model among several signals in the fair-value category, not a price target.
TRLV's technical score is 73/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $18.03 vs. price $10.90 (+65.5%); Earnings per share (EPS) growth: 26.6%; Free cash flow growth: 53.6%.
Based on the real signals StockIQ computed: Net margin: -10.3% (negative); Operating margin is eroding over time; ATR: 5.6% of price.
StockIQ has no recorded dividend payment history for TRLV.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 0 filings.
No recent insider transaction filings found for this stock.
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
5,117,058 shares short as of 2026-09-15 · vs. 1,444,593 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
62.5% of trading volume this week was short selling, vs. 54.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology